From identification to functional characterization of cyriotoxin-1a, an antinociceptive toxin from the spider Cyriopagopus schioedtei.
Autor: | Gonçalves TC; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France.; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France., Benoit E; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France.; Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR CNRS/Université Paris-Sud 9197, Université Paris-Saclay, Gif-sur-Yvette, France., Kurz M; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Lucarain L; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Fouconnier S; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Combemale S; Smartox Biotechnology, Saint-Egrève, France., Jaquillard L; Smartox Biotechnology, Saint-Egrève, France., Schombert B; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Chambard JM; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Boukaiba R; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Hessler G; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Bohme A; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France., Bialy L; Integrated Drug Discovery-Synthetic Molecular Design, Sanofi R&D, Frankfurt, Germany., Hourcade S; Neuroscience Therapeutic Area, Neurodegeneration Research, Sanofi R&D, Chilly-Mazarin, France., Béroud R; Smartox Biotechnology, Saint-Egrève, France., De Waard M; Smartox Biotechnology, Saint-Egrève, France.; Institut du Thorax, Inserm UMR 1087/CNRS UMR 6291, LabEx 'Ion Channels, Science and Therapeutics', Nantes, France., Servent D; Service d'Ingénierie Moléculaire des Protéines (SIMOPRO), CEA, Université Paris-Saclay, Gif-sur-Yvette, France., Partiseti M; Integrated Drug Discovery-High Content Biology, Sanofi R&D, Vitry-sur-Seine, France. |
---|---|
Jazyk: | angličtina |
Zdroj: | British journal of pharmacology [Br J Pharmacol] 2019 May; Vol. 176 (9), pp. 1298-1314. Date of Electronic Publication: 2019 Apr 09. |
DOI: | 10.1111/bph.14628 |
Abstrakt: | Background and Purpose: The Na Experimental Approach: We used high throughput screening of a large venom collection using automated patch-clamp experiments on human voltage-gated sodium channel subtypes and then in vitro and in vivo electrophysiological experiments to characterize the active peptides that have been purified, sequenced, and chemically synthesized. Analgesic effects were evaluated in vivo in mice models. Key Results: We identified cyriotoxin-1a (CyrTx-1a), a novel peptide isolated from Cyriopagopus schioedtei spider venom, as a candidate for further characterization. This 33 amino acids toxin belongs to the inhibitor cystine knot structural family and inhibits hNa Conclusions and Implications: The pharmacological profile of CyrTx-1a paves the way for further molecular engineering aimed to optimize the potential antinociceptive properties of this peptide. (© 2019 The British Pharmacological Society.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |